Bristol-Myers Squibb and PsiOxus Therapeutics Declare Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev


June 30, 2016

Bristol-Myers Squibb Company and PsiOxus Therapeutics, Ltd. have announced an exclusive clinical collaboration agreement for evaluating the tolerability, safety, and preliminary efficacy of Bristol-Myers Squibb’s Immuno-Oncology (I-O) agent Opdivo (nivolumab), in combination with PsiOxus’ enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, to treat a range of tumor types in late-stage cancer patients.

“This collaboration continues to expand our clinical development of Opdivo and explores how oncolytic viruses may provide a complementary mechanism to address tumors that are resistant to I-O therapy, We are excited to partner with PsiOxus to evaluate the combination of Opdivo and enadenotucirev to accelerate our understanding of its potential as a new therapeutic option for cancer patients,” said Jean Viallet, M.D., Global Clinical Research Lead, Oncology, Bristol-Myers Squibb.

As stated by John Beadle, M.D., Chief Executive Officer, PsiOxus: “We are delighted to collaborate with Bristol-Myers Squibb and to investigate enadenotucirev with Opdivo in several tumor types. They are our ideal partner since we share a common vision of exploring novel combinations such as enadenotucirev and Opdivo to expand the range of patients who potentially respond favorably to checkpoint inhibitor therapy.”



Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s